Marc Peeters, ESMO 2018 – Using Biomarkers to Guide Treatment in Colorectal Cancer
In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in the last 10 years and how treatment and prognosis can be guided using these biomarkers. This development is largely down to progress in technology, such as easier access to next generation sequencing, and the advent of liquid biopsies. Unfortunately, there are certain types of colorectal cancers with a poor prognosis, such as RAS- and BRAF-mutated tumours. There is still a need for biologics that can be added to standard chemotherapy in patients with these tumours.
1. What has been the most important recent therapeutic breakthrough in metastatic colorectal cancer? (0:11)
2. What is the prognostic significance of tumour location in colorectal cancer? (0:59)
3. What progress has been made in understanding the prognostic significance of molecular biomarkers in colorectal cancer? (1:45)
4. What are the most important unmet needs in colorectal cancer? (3:09)
5. What do you expect to be the highlights of this year’s ESMO congress? (4:21)
Speaker disclosures: Marc Peeters has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Gastrointestinal Cancers
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!